Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Allergy, Peanut Allergy

In brief

The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.

Key facts

Study ID
NCT07003919
Run by
DBV Technologies
People needed
480
Starts
2025-06-24
Expected to finish
2028-05-01
Last updated by the study team
2026-07-22

Who can join

Age: 1 and older, up to 3. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.